Virbac SA is primarily active in the animal health industry.

The main competitors of Virbac SA in the market include Boehringer Ingelheim Animal Health, Zoetis Inc., Elanco Animal Health, and Merck Animal Health.

Virbac SA is a reputable company with a rich history in the animal health industry. Founded in 1968, Virbac has established itself as a global leader in providing innovative solutions for the well-being of companion animals and livestock. With a strong focus on research and development, Virbac offers a wide range of pharmaceutical and biological products, as well as advanced diagnostics and nutritional solutions. The company's commitment to high-quality standards and sustainable practices has earned it a solid reputation among veterinarians and pet owners worldwide. Virbac SA continues to drive growth and innovation while remaining dedicated to improving animal health and welfare.

Virbac SA, a leading animal health company, has achieved several significant milestones. Over the years, the company has successfully expanded its global presence, establishing operations in numerous countries. It has consistently delivered innovative solutions and breakthrough products, addressing various animal health challenges. Virbac SA has also been actively involved in research and development, focusing on creating advanced pharmaceuticals and vaccines for the betterment of animal well-being. With a strong commitment to quality and customer satisfaction, the company has earned recognition as a trusted partner for veterinarians and pet owners worldwide.

Virbac SA is primarily present in various countries and regions around the world. Some of the key areas where the company has a significant presence include Europe, North America, and Asia. With its headquarters in Carros, France, Virbac SA has a strong foothold in the European market. The company's operations also extend to North America, particularly in the United States and Canada, where it caters to the needs of veterinarians, pet owners, and livestock farmers. Additionally, Virbac SA has a growing presence in Asia, serving customers in countries such as China, India, and Japan.

Virbac SA represents strong values and a dedicated corporate philosophy. As a leading animal health company, Virbac is committed to improving the health and wellbeing of animals worldwide. They prioritize innovation, quality, and expertise in developing and manufacturing a wide range of pharmaceutical products and vaccines for both companion animals and livestock. Virbac's corporate philosophy revolves around a deep respect for animals and the environment, as they strive to create sustainable solutions that contribute to the overall health and welfare of animals. With their unwavering commitment to research, Virbac is dedicated to providing effective and safe products that meet the specific needs of veterinarians and pet owners.

Analysts currently set an average price target of 415.03 EUR for the Virbac stock (median: 417.18 EUR), implying +23.0 % versus the latest price. The consensus is based on 16 analyst ratings.

Virbac Analyst Price Targets 2026

16 analysts currently rate the Virbac stock: 13 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Virbac to generate revenue of 1.55 B EUR and earnings per share of 20.39 EUR.

Virbac Analyst Price Targets 2026

The Virbac share (VIRP.PA) is listed on 7 stock exchanges, including: Frankfurt (V16.F), München (V16.MU), Düsseldorf (V16.DU), London (0NM7.L), Paris (VIRP.PA).

Virbac SA is an internationally active animal medicine manufacturer headquartered in France. The company was founded in 1968 and operates in around 100 countries today. Virbac specializes in the production and distribution of products for dogs, cats, livestock, horses, and other pets. The business model of Virbac SA is based on the development, production, and distribution of animal medicines, as well as services for veterinarians and pet owners. The company offers a wide range of products for various animal species. These products cover a broad spectrum of applications, including parasite protection, wound care, antibiotics, feed additives, diagnostic systems, and hygiene supplies. Virbac is also active in veterinary medicine, where the company offers specialized products for cardiology, neurology, oncology, and other diseases. Virbac also has its own research and development department, which focuses on the development of new products and technologies. The company divides its products into three main categories: veterinary practice, livestock farming, and pet care. Veterinary practice products include ear products, eye products, painkillers, antibiotics, as well as dental and oral care. Livestock farming products include products for cattle, pigs, poultry, and other animals, including vaccines, dewormers, and nutritional supplements. In the pet care category, Virbac offers protection products against fleas, ticks, and other parasites, as well as nutritional supplements and grooming products. Virbac SA has a dynamic business model based on continuous innovation and research. Over the years, the company has built a strong presence and established itself as a leading provider in veterinary medicine. Virbac continuously invests in research and development of new products and technologies to expand and improve its product range. The company also pursues an active business strategy to expand its presence in new geographic regions. In 2019, for example, Virbac expanded its presence in Southeast Asia by opening a new production facility in Vietnam. Overall, the business model of Virbac SA is designed for sustainable growth. The company aims to strengthen its global presence and further expand its leading position in veterinary medicine. With a wide range of products and services, strong research and development capacity, and a solid business strategy, Virbac is well-positioned to continue to be successful in the coming years.

The expected revenue of Virbac is 1.55 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Virbac is 171.47 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Virbac is currently 16.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Virbac stock.

The price-to-sales ratio (P/S) of Virbac is currently 1.83. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Virbac stock.

The Eulerpool Quality Score for Virbac is 7/10.

The ISIN of Virbac is FR0000031577. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Virbac is 874929. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Virbac is VIRP.PA. The ticker symbol is used to trade Virbac shares on the stock exchange.

Over the past 12 months, Virbac paid a dividend of 1.45 EUR . This corresponds to a dividend yield of about 0.43 %. For the coming 12 months, Virbac is expected to pay a dividend of 1.45 EUR.

The current dividend yield of Virbac is 0.43 %.

Virbac pays a dividend, distributed in the months of , , , .

Virbac paid dividends every year for the past 5 years.

For the upcoming 12 months, dividends amounting to 1.45 EUR are expected. This corresponds to a dividend yield of 0.43 %.

Virbac is assigned to the 'Health' sector.

To receive the latest dividend of Virbac from amounting to 1.45 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Virbac distributed 1.32 EUR as dividends.

The dividends of Virbac are distributed in EUR.